BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27

• Press Releases

  IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

  July 27, 2026

   · 

  8 min read
• Press Releases

  Bambusa Therapeutics Reports Potentially Transformative Preliminary Proof-of-Concept Results for BBT001 in Atopic Dermatitis, Reinforcing Its Best-in-Disease Potential

  July 27, 2026

   · 

  9 min read
• 

  Mergers & acquisitions

  Argenx deepens immuno expertise with $2.2B Forte Biosciences buy

  The star of the takeover is Forte Biosciences’ investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.

  July 27, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Approvals

  Otsuka’s ADHD approval opens up new drug class with $615M opportunity

  Otsuka Pharmaceutical plans to launch Simtriyo—the first norepinephrine, dopamine, serotonin reuptake inhibitor—later this year following scheduling by the U.S. Drug Enforcement Agency.

  July 27, 2026

   · 

  2 min read

   · 

  Tristan Manalac